Exicure, Inc. Announces Proposed Settlement of Securities Class Action Litigation

Business Wire

10 Sep 2024

CHICAGO, September 09, 2024--(BUSINESS WIRE)--Exicure, Inc. (Nasdaq: XCUR, the "Company") announced today that it has entered into an agreement with plaintiffs to settle Colwell v. Exicure, Inc. et al., Case No. 1:21-CV-06637, a previously disclosed securities class action lawsuit pending in the United States District Court for the Northern District of Illinois (the "Court"). The settlement is subject to Court approval, and plaintiffs filed a motion for preliminary approval of the settlement with the Court on September 6, 2024.

The settlement does not constitute any admission by the Company of any liability or wrongdoing. Nonetheless, the Company believes it is beneficial to resolve the case as further litigation would be burdensome and protracted.

About Exicure

Exicure, Inc. has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. Following its recent restructuring and suspension of clinical and development activities, the Company is exploring strategic alternatives to maximize stockholder value, both with respect to its historical biotechnology assets and more broadly. For further information, see www.exicuretx.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240909816210/en/

Contacts

Josh Miller
847-673-1700
media@exicuretx.com

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2466147390"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2466147390\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2466147390?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/YL9vxvghjbElQNMbE_THUw--~B/aD02MDA7dz0yNDMxO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/69195881505446441c5fa77bc4b431d9","is_english":true,"pubTime":"2024-09-10 06:53","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2466147390","market":"us","top_or_hot":-1,"title":"Exicure, Inc. Announces Proposed Settlement of Securities Class Action Litigation","media":"Business Wire","content":"<html><body>\n<figure>\n<img border=\"0\" height=\"600\" src=\"https://s1.yimg.com/uu/api/res/1.2/qFI1GGHuzrDJMXv0YewuXg--/cT03NTthcHBpZD15dmlkZW9mZWVkczs-/https://media.zenfs.com/en/business-wire.com/69195881505446441c5fa77bc4b431d9\" title=\"\" width=\"2431\"/>\n<figcaption></figcaption>\n</figure>\n<p><b>CHICAGO, September 09, 2024</b>--(BUSINESS WIRE)--<a href=\"https://laohu8.com/S/XCUR\">Exicure, Inc.</a> (Nasdaq: XCUR, the \"Company\") announced today that it has entered into an agreement with plaintiffs to settle Colwell v. Exicure, Inc. et al., Case No. 1:21-CV-06637, a previously disclosed securities class action lawsuit pending in the United States District Court for the Northern District of Illinois (the \"Court\"). The settlement is subject to Court approval, and plaintiffs filed a motion for preliminary approval of the settlement with the Court on September 6, 2024.</p>\n<p>The settlement does not constitute any admission by the Company of any liability or wrongdoing. Nonetheless, the Company believes it is beneficial to resolve the case as further litigation would be burdensome and protracted.</p>\n<p><b>About Exicure</b></p>\n<p>Exicure, Inc. has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. Following its recent restructuring and suspension of clinical and development activities, the Company is exploring strategic alternatives to maximize stockholder value, both with respect to its historical biotechnology assets and more broadly. For further information, see www.exicuretx.com.</p>\n<p><span>View source version on businesswire.com: </span><span>https://www.businesswire.com/news/home/20240909816210/en/</span></p>\n<p><b>Contacts</b></p>\n<p>Josh Miller<br/>847-673-1700<br/>media@exicuretx.com<br/><br/></p></body></html>","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta content=\"text/html; charset=utf-8\" http-equiv=\"Content-Type\"/>\n<meta content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\" name=\"viewport\"/>\n<meta content=\"telephone=no,email=no,address=no\" name=\"format-detection\"/>\n<title>Exicure, Inc. Announces Proposed Settlement of Securities Class Action Litigation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nExicure, Inc. Announces Proposed Settlement of Securities Class Action Litigation\n</h2>\n<h4 class=\"meta\">\n\n\n2024-09-10 06:53 GMT+8   <a href=\"https://finance.yahoo.com/news/exicure-inc-announces-proposed-settlement-225300488.html\"><strong>Business Wire</strong></a>\n</h4>\n</header>\n<article>\n<div>\n<p>CHICAGO, September 09, 2024--(BUSINESS WIRE)--Exicure, Inc. (Nasdaq: XCUR, the \"Company\") announced today that it has entered into an agreement with plaintiffs to settle Colwell v. Exicure, Inc. et al...</p>\n<a href=\"https://finance.yahoo.com/news/exicure-inc-announces-proposed-settlement-225300488.html\">Source Link</a>\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://finance.yahoo.com/news/exicure-inc-announces-proposed-settlement-225300488.html","article_id":"2466147390","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/YL9vxvghjbElQNMbE_THUw--~B/aD02MDA7dz0yNDMxO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/69195881505446441c5fa77bc4b431d9"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2466147390","pubTimestamp":1725922380,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"CHICAGO, September 09, 2024----Exicure, Inc.  announced today that it has entered into an agreement with plaintiffs to settle Colwell v. Exicure, Inc. et al., Case No. 1:21-CV-06637, a previously disclosed securities class action lawsuit pending in the United States District Court for the Northern District of Illinois . The settlement is subject to Court approval, and plaintiffs filed a motion for preliminary approval of the settlement with the Court on September 6, 2024.The settlement does not constitute any admission by the Company of any liability or wrongdoing. Nonetheless, the Company believes it is beneficial to resolve the case as further litigation would be burdensome and protracted.Exicure, Inc. has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. Following its recent restructuring and suspension of clinical and development activities, the Company is exploring strategic alt","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","XCUR":"Exicure, Inc."},"translate_title":"Exicure，Inc.宣布拟议的证券集体诉讼和解","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"XCUR":1},"content_text":"CHICAGO, September 09, 2024--(BUSINESS WIRE)--Exicure, Inc. (Nasdaq: XCUR, the \"Company\") announced today that it has entered into an agreement with plaintiffs to settle Colwell v. Exicure, Inc. et al., Case No. 1:21-CV-06637, a previously disclosed securities class action lawsuit pending in the United States District Court for the Northern District of Illinois (the \"Court\"). The settlement is subject to Court approval, and plaintiffs filed a motion for preliminary approval of the settlement with the Court on September 6, 2024.\nThe settlement does not constitute any admission by the Company of any liability or wrongdoing. Nonetheless, the Company believes it is beneficial to resolve the case as further litigation would be burdensome and protracted.\nAbout Exicure\nExicure, Inc. has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. Following its recent restructuring and suspension of clinical and development activities, the Company is exploring strategic alternatives to maximize stockholder value, both with respect to its historical biotechnology assets and more broadly. For further information, see www.exicuretx.com.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20240909816210/en/\nContacts\nJosh Miller847-673-1700media@exicuretx.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1}}}